← Home
Ono Pharmaceutical
-9.86%
Pharma / Pharmaceuticals, Healthcare
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-03-02 20:00:00 | Ono Pharma Announces New Drug Discovery Collaboration With Congruence Therapeutics In The Priority Areas Of Neurology And Immunology Osaka, japan & montreal--(business wire)--ono pharmaceutical co., ltd. (headquarters: osaka, japan; president: toichi takino; “ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with congruence therapeutics (headquarters: montreal, quebec, canada; ceo: clarissa desjardins; “congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. in december 2024, we entere. |
| 2026-02-17 07:00:00 | Deciphera Pharmaceuticals Announces U.s. Food And Drug Administration Acceptance For Filing Of New Drug Application For Tirabrutinib In Patients With Relapsed Or Refractory Pcnsl Osaka, japan & waltham, mass.--(business wire)--deciphera pharmaceuticals, a member of ono pharmaceutical co., ltd. (headquarters: osaka, japan; president and coo: toichi takino; “ono”), today announced that the u.s. food and drug administration (fda) has accepted for filing the new drug application (nda) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primar. |
📰 Browse additional press releases for Ono Pharmaceutical!
Sign up for free or log in🙌 Join now to get "The Checklist Value Investor — A Smarter Way to Pick Stocks" at no cost